ImmunityBio (IBRX)
(Delayed Data from NSDQ)
$8.10 USD
-0.30 (-3.57%)
Updated May 15, 2024 04:00 PM ET
After-Market: $8.09 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
IBRX 8.10 -0.30(-3.57%)
Will IBRX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IBRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IBRX
Here's Why ImmunityBio (IBRX) Is a Great 'Buy the Bottom' Stock Now
ImmunityBio (IBRX)'s Technical Outlook is Bright After Key Golden Cross
IBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Qiagen (QGEN) Q3 Earnings and Revenues Surpass Estimates
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing
Other News for IBRX
Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024
ImmunityBio: Q1 Earnings Snapshot
The 3 Best Bargain Stocks to Buy in May 2024
Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday